Dr Andrew Clifton joins Concept Life Sciences as Head of Bioassay Development and Screening Technologies. Concept Life Sciences offers tailored preclinical services, including integrated drug discovery programmes.
Dr Clifton will be responsible for providing assay development and screening capabilities to support preclinical drug discovery projects from hit finding, through to candidate selection.
He has more than eighteen years’ experience in both large pharma and biotech, with roles at AstraZeneca and Redx Pharma.
His expertise is in biochemistry and pharmacology and he has experience across major drug target classes, including a wide variety of enzymes and GPCRs.
He has extensive experience of assay development and screening applied to hit finding, hit to lead and lead optimisation and has contributed to the delivery of multiple clinical candidates.
His therapy area experience includes oncology, inflammation/fibrosis and respiratory.
Prior to commencing his pharmaceutical career, Dr Clifton completed his doctoral training with Professor Sir Philip Cohen at the University of Dundee MRC Protein Phosphorylation Unit.
Dr Clifton, said: “Concept is generally recognised as a leading global provider of preclinical drug discovery services, and I look forward to building our assay development and screening capability to support integrated drug discovery projects. I also look forward to supporting the groups many integrated discovery and development partners, from virtual biotechs to big pharma.”
